Door opener for SomnoMed

SomnoMed has received approval to begin the commercialisation of the world’s first oral device for Obstructive Sleep Apnea (OSA) with the ability to objectively measure compliance rates and report back to the clinicians. This is a very important step for the efficacy of COAT ™ devices to clinicians/insurers and we believe this ability will act as a door opener to the prescribers and payers alike for mild to moderate sleep apnea. We upgrade our price target to A$3.23 and retain an Add recommendation. Report attached and the link to the blog site is here: (VIEW LINK)


1 stock mentioned

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter